# Acepodia

> Acepodia is a clinical-stage biotechnology company founded in 2017 and headquartered in Alameda,
> California, with operations in Taipei, Taiwan. It develops off-the-shelf allogeneic cell therapies
> for cancer and autoimmune disease using its Antibody-Cell Conjugation (ACC) and Antibody-Dual-Drugs
> Conjugation (AD2C) platforms. Acepodia is a therapeutics developer, not a software vendor, and runs
> no developer program.

<!--
generated: 2026-08-06
method: generated
source: apis.yml + live probes of www.acepodia.com on 2026-08-06
note: Generated by the API Evangelist enrichment pipeline. Acepodia does not publish an llms.txt of
      its own — https://www.acepodia.com/llms.txt returns the site's 404 page.
-->

## About

Acepodia was founded in 2017 by Dr. Patrick Y. Yang and Dr. Sonny Hsiao. Its core Antibody-Cell
Conjugation (ACC) technology derives from the bioorthogonal click chemistry developed in Professor
Carolyn Bertozzi's laboratory, work recognised with the 2022 Nobel Prize in Chemistry. ACC links
tumor-targeting antibodies directly to allogeneic immune effector cells — gamma delta 2 T cells and
natural killer cells — without genetic engineering, producing what the company calls antibody cell
effector (ACE) therapies. A second platform, AD2C, performs site-specific conjugation of multiple
linker-payloads to an antibody.

## Pipeline

- ACE1831 — anti-CD20 armed allogeneic gamma delta 2 T cell therapy; Phase 1 in non-Hodgkin lymphoma,
  with a program in IgG4-related disease.
- ACE2016 — anti-EGFR allogeneic gamma delta 2 T cell therapy for EGFR-expressing solid tumors;
  IND cleared by the FDA, Phase 1.
- AD2C-Oncology — GPC3-targeting program in hepatocellular carcinoma; preclinical.

## Site

- [Home](https://www.acepodia.com/)
- [About](https://www.acepodia.com/about/)
- [Leadership](https://www.acepodia.com/leadership/)
- [Technology](https://www.acepodia.com/technology/): ACC, gamma delta 2 T cells, oNK cells
- [Pipeline](https://www.acepodia.com/pipeline/)
- [Newsroom](https://www.acepodia.com/newsroom/): press releases, events and presentations,
  publications, media coverage
- [Press releases](https://www.acepodia.com/newsroom/press-releases/)
- [Partnerships](https://www.acepodia.com/partnerships/)
- [Careers](https://www.acepodia.com/careers/)
- [Contact](https://www.acepodia.com/contact/)
- [Privacy Policy](https://www.acepodia.com/legal/privacy/)
- [Terms of Use](https://www.acepodia.com/legal/terms-of-use/)
- [LinkedIn](https://www.linkedin.com/company/acepodia/)

## APIs

Acepodia publishes no API. As of 2026-08-06 there is no developer portal, no API documentation, no
SDK or client library in any public package registry, no OpenAPI/AsyncAPI/GraphQL contract, no MCP
server and no A2A agent card. No `api.`, `developer.`, `docs.`, `portal.`, `app.`, `status.` or
`trust.` host resolves for acepodia.com (all NXDOMAIN), and no `acepodia` GitHub organisation exists.
Every /.well-known/ discovery path and every conventional spec path on www.acepodia.com returns the
site's own HTML 404 page. The company's published sitemap.xml lists 38 URLs, all corporate.

The only automation-adjacent route on the property is `/public/lineBot`, a callback for Acepodia's own
LINE official account, which the site's robots.txt disallows. It is not a developer offering and is
not catalogued here as an API.

Agents looking for a machine-readable interface to Acepodia should expect none. Company information
is available only as HTML pages on www.acepodia.com; investor and clinical information is published
through press releases and regulatory filings rather than through a data interface.

## API Evangelist profile

- [apis.yml](https://raw.githubusercontent.com/api-evangelist/acepodia/refs/heads/main/apis.yml)
- [Well-known / discovery probe results](https://raw.githubusercontent.com/api-evangelist/acepodia/refs/heads/main/well-known/acepodia-well-known.yml)
- [Domain security probe](https://raw.githubusercontent.com/api-evangelist/acepodia/refs/heads/main/security/acepodia-domain-security.yml)